AstraZeneca Pharma India Receives ₹148.66 Crore Demand Notice from NPPA
AstraZeneca Pharma India received a demand notice from NPPA for ₹148.66 crore due to alleged overcharging on Symbicort Turbuhaler. The demand includes interest up to August 20, 2026, and is for the period May 2016 to November 2025. The company is evaluating legal actions.
The demand notice is for a substantial amount of ₹148.66 crore, which could have a significant financial impact on the company.
The company has received a significant demand notice from a regulatory authority, which is a negative development.
AstraZeneca Pharma India Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The notice, dated July 29, 2026, demands a payment of ₹1,48,65,83,590, inclusive of interest calculated up to August 20, 2026. This demand is related to the Symbicort Turbuhaler 160/4.5 (Inhaler) and pertains to alleged overcharging for the period from May 2016 to November 2025.
The company had previously received a show cause notice on September 11, 2025. AstraZeneca Pharma India is currently evaluating the demand notice and is considering appropriate legal actions. The amount is payable within 30 days from the receipt of the notice. The company has disclosed this action under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What to do with a filing like this
AstraZeneca Pharma India Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by AstraZeneca Pharma India Limited. Read the original for the full detail.